このエントリーをはてなブックマークに追加
ID 71051
FullText URL
Author
Nagao, Shoji Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Fujikawa, Atsushi Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Tanaka, Yui Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Tanioka, Momoko Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Imatani, Ryoko Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Tani, Yoshinori Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sugihara, Hanako Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Okamoto, Kazuhiro Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Matsuoka, Hirofumi Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Ida, Naoyuki Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Haraga, Junko Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Ogawa, Chikako Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID
Masuyama, Hisashi Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
Abstract
Epithelial ovarian cancer is predominantly characterized by peritoneal dissemination, providing a strong biological rationale for intraperitoneal (IP) chemotherapy. Although IP cisplatin-based regimens have demonstrated substantial survival benefits in pivotal randomized trials, toxicity and catheter-related complications limit their widespread adoption. IP carboplatin has emerged as a pragmatic alternative with improved tolerability while preserving its pharmacokinetic advantages. This review summarizes the biological and pharmacological rationale for IP carboplatin and critically examines the clinical evidence, with a particular emphasis on the Intraperitoneal Carboplatin for Ovarian Cancer (iPocc) trial and its divergence from Gynecologic Oncology Group (GOG)-252. We further discuss the potential applicability of IP carboplatin beyond the traditional setting of minimal residual disease, including patients undergoing neoadjuvant chemotherapy and interval debulking surgery, as well as its possible use in the contemporary era of maintenance therapy. Collectively, the accumulated evidence supports renewed consideration of IP carboplatin as a versatile component in modern ovarian cancer management.
Keywords
ovarian cancer
intraperitoneal chemotherapy
carboplatin
dose-dense TC therapy
homologous recombination deficiency
PARP inhibitor
neoadjuvant chemotherapy
Published Date
2026-02-27
Publication Title
Cancers
Volume
volume18
Issue
issue5
Publisher
MDPI AG
Start Page
764
ISSN
2072-6694
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2026 by the authors.
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.3390/cancers18050764
License
https://creativecommons.org/licenses/by/4.0/
Citation
Nagao, S.; Fujikawa, A.; Tanaka, Y.; Tanioka, M.; Imatani, R.; Tani, Y.; Sugihara, H.; Okamoto, K.; Matsuoka, H.; Ida, N.; et al. The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation. Cancers 2026, 18, 764. https://doi.org/10.3390/cancers18050764